NV-QUECTEL-WIRELESS
4.1.2023 14:01:53 CET | Business Wire | Press release
CES, Quectel Wireless Solutions, a global IoT and automotive solutions provider, today announces its new automotive grade 5G NR modules, the AG59x series. The new modules deliver a wide range of enhancements including multi-gigabit cellular connectivity, C-V2X PC5 direct communications, improved location services, a high-performance multicore application processor as well as strengthened security, making it an ideal solution in supporting the next generation automotive applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230104005509/en/
(Graphic: Business Wire)
Based on the AEC-Q100 qualified Qualcomm chipsets, the new range of modules include the AG59xH series, which integrates the Qualcomm SA525M and the AG59xE series featuring the Qualcomm SA522M inside. Similar to Quectel’s other automotive products, the AG59x modules comply with the international IATF 16949:2016 automotive quality management system to address the demanding requirements of automotive devices. Featuring high robustness, the AG59x series delivers strong performance even under high temperature environments.
“We are very excited to bring the highly anticipated 5G NR Release 16 module to global automotive markets. Its significant improvements in latency and ultra-reliability are critical in supporting autonomous driving,” said Manfred Lindacher, Vice President of Global Sales, Automotive International, Quectel Wireless Solutions. “Combined with its many other advantages, our AG59x series will be an excellent choice for a wide range of automotive applications including telematics boxes, telematics control units, C-V2X systems, on-board units, and roadside units.”
Meeting the 3GPP Release 16 specification and supporting both 5G NR standalone (SA) and non-standalone (NSA) modes, the AG59x modules are backward-compatible with existing LTE, WCDMA and GSM networks, allowing them to be connected in areas without current 5G NR deployment. Additionally, its Dual SIM Dual Standby (DSDS) technology can help tackle poor signal coverage when needed.
The AG59x supports 4 x 4 downlink multiple input multiple output (MIMO) technology which greatly improves wireless communication performance and optimizes data speeds. The AG59xH delivers maximum downlink rates of 4.3Gbps and uplink rates of 1Gbps for 5G NR, while the AG59xE provides up to 2.4Gbps peak downlink rate and 550Mbps uplink rate. Their faster data speeds ensure that user emergency data and diagnostic data can be transferred in real time for increased reliability.
Supporting optional C-V2X PC5 direct communications, the AG59x brings superior performance in vehicle-to-vehicle (V2V) and vehicle-to-roadside infrastructure (V2I) communications for improved traffic efficiency and safety. The module integrates a powerful application processor with up to 20KDMIPS computing power available to run C-V2X stack and applications. It also has an integrated ECDSA engine fulfill C-V2X verification capability.
Additionally, the highly integrated AG59x module provides flexible GNSS positioning services including L1+L5 / L1+L2 (optional) dual frequency GNSS, dead reckoning (DR), and PPE + Data Correction Service to achieve quick and precise location positioning services.
Available in LGA packages, the AG59x is pin-to-pin compatible with Quectel’s previous generation 5G NR automotive modules AG55xQ and AG57xQ, which allows global OEM and Tier 1 customers to upgrade their devices easily and seamlessly through a simple drop-in replacement. The AG59x provides a variety of interfaces including PCIe 3.0, USB 2.0 & 3.1, SDIO, I2S, SPI, I2C, UART, PCM, ADC, (U)SIM, 1PPS, GPIOs. It also supports RGMII and SGMII interfaces at the same time which greatly improves the adaptability of in-vehicle Ethernet.
The Quectel AG59x series is complemented by its range of high-performance antennas, already in use in the autonomous car market. Customized antennas are also supplied to fit for various vehicle setup environments. In particular, Quectel’s range of combo antennas, which integrate multiple technologies such as 5G, 4G, and GNSS, offer a highly flexible and reliable antenna solution for automotive applications.
Engineering samples of the AG59x modules will be available in the first half of 2023, with multiple variants targeting global markets.
Find out more about this module series at CES 2023 on booth 10862.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services.
Our growing global team of over 6,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005509/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom